logo
PARTNER WITH US
Help Desk :+91 40 2348 0230

Our mission is to ensure the generation of accurate and precise findings.

GET UPDATE

Please enter subscribe form shortcode

CHEACK INSTAGRAM POST

Please enter instagram feed shortcode

Finoso Pharma at IPHEX 2024: Join Us for Innovation and Partnership Opportunities

Finoso Pharma > News, Events & Blog > GEMOLOGICAL > Finoso Pharma at IPHEX 2024: Join Us for Innovation and Partnership Opportunities
August 23, 2024 No Comments

Finoso Pharma at IPHEX 2024: Join Us for Innovation and Partnership Opportunities

Finoso Pharma is excited to participate in IPHEX 2024, a premier event bringing together global pharmaceutical leaders, regulators, and industry professionals. We are dedicated to innovation, quality, and collaboration, and this event provides the perfect platform to showcase our latest advancements and explore new business opportunities.

Why Visit Us?

  • *Innovation*: Discover our cutting-edge formulations and biosimilars, designed to meet the highest standards of safety and efficacy.
  • *Quality*: Learn about our world-class manufacturing facilities, which comply with the strictest international regulatory standards.
  • *Partnerships*: Explore strategic collaborations, including co-development, contract manufacturing, and licensing agreements.

Opportunities at Our Booth

  • *Product Portfolio Expansion*: Explore how our diverse range of pharmaceutical products can enhance your offerings.
  • *Contract Manufacturing*: Leverage our expertise to bring your products to market efficiently.
  • *Co-Development Projects*: Collaborate with our R&D team on innovative new products.

Visit Us at IPHEX 2024

  • *Event*: IPHEX 2024
  • *Hall No*: H3
  • *Booth No*: 82

We look forward to meeting you at IPHEX 2024 and discussing how Finoso Pharma can support your business goals. Don’t miss this opportunity to connect with us and explore how we can drive mutual growth through innovation and collaboration.

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Recent Posts

Recent Comments

No comments to show.

Category

Recent Post

August 23, 2024

Finoso Pharma at IPHEX 2024: Join Us

Priyaranjan-Pattanaik

Priyaranjan Pattanaik holds Bachelor and Master Degree in Pharmaceutical Technology from Biju Patnaik University, Bhubaneswar.

He has over 12 years of experience in formulation research. Prior to his stint with Finoso Pharma, he worked with R&D centres of Indian leading pharma companies like Micro labs, Medreich, Indoco Remedies, Hetero Labs and Optimus Pharma. He has varied experience that encompasses activities from formulation development to product approvals for the US, Canada, Europe and other regulated markets along with other emerging markets. He managed product development programs from initiation, development strategy, risk assessment analysis, infringement analysis and regulatory filings of generic products.

This will close in 0 seconds

Sanjay-Pasi

Sanjay holds a Bachelor’s Degree in Chemistry from Mumbai University, Maharashtra, India and Master’sDegree in Analytical Chemistry from Mumbai University, Maharashtra, India. He has over 16 years of experience in Analytical Research and Development of APIs and various finished dosage forms. Prior to his stint at Finoso Pharma, he worked with companies like CIPLA, Dr. Reddy’s Laboratoriesand Aizant.

He has extensive knowledge and experience in Method Development, Method Validations, Method Transfers, Laboratory Management (LIMS, CFR Part 11 Compliance), Stability Studies, and Packaging Material Testing. He is an expert in handling wide range of analytical instruments including HPLC, UPLC, TGA, DSC, AAS, GC with TCD and ECD, Laser Diffraction Particle Size Analyzers, pXRD, UV, FTIR etc. He has vast experience in end to end delivery of various NDA, ANDA & NCE-1 projects.

He has developed and validated analytical methods for Assay, Related Substances, and Dissolutions etc. for various types of dosage forms like tablets, pellets, injectable, inhalers, gels, suspensions, syrups, capsules, ointments and creams. He has adequate exposure in handling regulatory questions on analytical methods from USFDA, UK MHRA, Health Canada and other leading agencies.

This will close in 0 seconds

dilip

Director (Board Member of Finoso Management) - Finoso Pharma & Chief Technical Officer - Vivimed Labs

Dillip obtained his Master’s in Pharmaceutical & Pharmaceutical Technology from LM college of Pharmacy, Ahmedabad, Gujarat India. He has about 15 plus years of work experience in Research & Development, Business Development and Manufacturing Plant operations.

He worked in the Innovation &Generic Pharmaceutical industry for over 15 years, handling product and process development activities. During this time, he was responsible for developing several solid and liquid dosage form products and got several ANDAs approved by the US FDA, MHRA, Health Canada, TGA etc. After leading formulation Development teams in companies like ZydusCadila, Mylan Laboratories Ranbaxy Research Laboratory, India & Dr.Reddy’s Laboratories he moved to Aizant for setting up In house products portfolio. Under his visionary leadership Aizant filed & got approval for multiple complex generic and NCE-1 products.After his successful stint at Aizant, he took the responsibility asPresident R&D and Operations at Optimus pharma where he played important role in reforming the business model, under his visionary and vibrant leadership Optimus pharma observed the peaks of growth. Optimus was amongst few first Indian companies to launch & get approval for anti-corona Favipiravir Tablets.

He has rich experience that encompasses activities from formulation development to product approvals for the US, Europe and other regulated markets. He managed entire product development program from molecule selection, development strategy, risk assessment analysis, infringement analysis and regulatory filings of generic products. He has several patents, at various stages, to his credit. He was exposed to generic product development from Para I to Para IV filings and he has substantial experience in filing NDAs as well.

Dillip has hands on experience in developing formulations of Antidepressant, Anti-allergic, Antiviral, Anti-diabetic and Cardiovascular drugs. His research projects included development of Para IV / modified release / sustained release generic formulations based on matrix / palletization / osmotic delivery technologies for oral solid dosage forms. He has several publications and research papers to his credit.

He joined Finoso Pharma in Aug 2020 and has been running the company successfully ever since as its Director& CTO.

This will close in 0 seconds

Formulation Development

  • Literature Search and Technical Patent Review
  • Pre-Formulation Development
  • Drug-Excipient Compatibility Studies
  • Formulation Development and Optimization
  • Process Development and Optimization
  • Scale-Up and Technology Transfer
  • Process Validation Studies
  • Packaging Development Studies

This will close in 0 seconds

Manufacturing Facility

  • FDA and cGMP Complaint Facilities
  • Aseptic and non-sterile manufacturing environment
  • Unit 1: Oral Solids, Oral Liquids, Sachets and other oral dosage forms
  • Unit 2: Ophthalmic, Nasal Sprays and Otic dosage forms
  • Separate area for Pilot batches for EU/US/Canada client

This will close in 0 seconds

Quality and Regulatory

  • CTD Filings
  • Dossiers Meeting Various Global Requirements
  • IND / NDA and ANDA Support Documentation
  • Post Approval Changes and Related Regulatory Filings
  • Licensing

This will close in 0 seconds

Other Services

  • Contract ICH Stability
  • Vendor Development and Qualification
  • Quality Auditing
  • Quality Services
  • Sourcing Services
  • Portfolio Management Services

This will close in 0 seconds

Analytical Development

  • Analytical Method Development for Assay, Content Uniformity, Related Substances, Dissolution etc.
  • Analytical Method Validation
  • Forced Degradation Studies
  • Method and Site Transfers
  • Specification Development
  • ICH Stability Studies and Stability Sample Analysis
  • R&D Sample Analysis

This will close in 0 seconds